CANbridge Receives Hong Kong Department of Health Market Approval for Nerlynx®
Nov 05, 2019
CANbridge Pharmaceuticals’ Hunterase® Granted Priority Review by the Chinese National Medical Products Administration
Sep 09, 2019
CANbridge Pharmaceuticals Appoints Senior Vice President, Rare Disease Commercial Operations
Jul 30, 2019
CANbridge Pharmaceuticals Submits New Drug Application for Hunterase® for the Treatment of Hunter Syndrome in China
Jul 29, 2019
CANbridge Pharmaceuticals Appoints Chief Financial Officer and Interim Chief Medical Officer
Apr 25, 2019
CANbridge Pharmaceuticals and WuXi Biologics Expand Rare Disease Therapeutics Partnership
Jan 08, 2019
CANbridge Pharmaceuticals and GC Pharma Announce Greater China Licensing Agreement for Hunterase™ for Hunter Syndrome
Jan 07, 2019